#United States #New York #BrainStorm #ALS #Dr. Heiman-Patterson

BrainStorm Cell Therapeutics Announces Upcoming KOL Webinar on ALS

Webinar Overview

On December 11, 2024, BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a prominent developer of therapies using adult stem cells for neurodegenerative diseases, is slated to host a pivotal webinar targeting key opinion leaders (KOL) in the field of amyotrophic lateral sclerosis (ALS). The event is set to commence at 10:00 AM ET and will spotlight the latest advancements in ALS treatment, offering invaluable insights to both medical professionals and stakeholders.

Featured Speaker

The webinar will showcase Dr. Terry Heiman-Patterson, an esteemed KOL from the Lewis Katz School of Medicine at Temple University. With decades of experience, Dr. Heiman-Patterson is a recognized leader in ALS research and care. Her contributions have significantly shaped the treatment landscape, making her insights critical for those involved in ALS management.

Dr. Heiman-Patterson will delve into the current treatment landscape for ALS, providing attendees with a comprehensive overview of the latest developments and ongoing clinical trials. Her expertise is complemented by her extensive background, which includes directing the MDA/ALS Center of Hope and serving as President of the ALS Hope Foundation.

New Developments in ALS Treatment

The webinar will also give BrainStorm’s management team a platform to discuss the planned Phase 3b registrational clinical trial for NurOwn®, a revolutionary therapy utilizing autologous MSC-NTF cells. This innovative treatment has garnered attention due to its potential to alter the trajectory of ALS, a debilitating condition for which treatment options have traditionally been limited.

BrainStorm aims to demonstrate the efficacy of NurOwn through the successful completion of the randomized portion of the Phase 3b trial. Success in this trial is expected to support a Biologics License Application (BLA), potentially paving the way for FDA approval to offer NurOwn to ALS patients across the United States.

Live Q&A Session

Following the presentations, a live Q&A session will be held, giving attendees the opportunity to engage directly with Dr. Heiman-Patterson and the BrainStorm team. This interactive component aims to foster discussion around the challenges and innovations in ALS treatment and research, allowing participants to address their queries and concerns directly with experts in the field.

About Dr. Terry Heiman-Patterson

Dr. Heiman-Patterson stands as a beacon in ALS care, having orchestrated numerous clinical trials that set key benchmarks in treatment methodologies. A prolific author, she has contributed over 50 scientific papers to the field and received accolades for her commitment to improving patient care. Her extensive research spans more than three decades, emphasizing the importance of innovative approaches in treating ALS.

About BrainStorm Cell Therapeutics Inc.

BrainStorm focuses on pioneering new treatments for neurodegenerative diseases. The company's NurOwn® platform is indicative of their commitment to harnessing the body's own cells for therapeutic benefit. With Orphan Drug designation from both the FDA and the European Medicines Agency (EMA) for ALS, BrainStorm continues to explore the intricacies of adult stem cell therapies that hold promise for patients suffering from this devastating disease.

Conclusion

As BrainStorm prepares to engage with the community through the upcoming KOL webinar, the focus remains on advancing understanding and treatment of ALS. With experts like Dr. Heiman-Patterson leading the discussion, the webinar promises to be a significant event for those involved in ALS research and patient care. Don't miss this opportunity to learn from leading figures in the field on December 11, 2024.